Redesigned MabThera for Treatment of ALS

News   May 26, 2017 | Original Story from Ben-Gurion University of the Negev

 
Academic Redesigns FDA-Approved MabThera to Treat ALS

Dr. Rachel Lichtenstein, Ben-Gurion University of the Negev

 
 
 
 

RELATED ARTICLES

No Needles Needed: Flu immunization by patch

News

Researchers have successfully trialled a patch of dissolving microneedles for the delivery of vaccines.

READ MORE

Rare Gene Mutation Reveals How the Body Responds to the Common Cold

News

Analyzing a rare genetic mutation in a child helped researchers discover how the immune system responds to common cold viruses.

READ MORE

360 New Disease Models Identified in Lab Mouse Study

News

The research, which generated over 20 million pieces of data, has found 360 new disease models and provides 28,406 new descriptions of the genes’ effects on mouse biology and disease.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Cell Science Drug Discovery Neuroscience

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE